Small Cap Feast
Small Cap Feast – 15 January 2019
Dish of the Day:
No Joiners Today
No Joiners Today
Off the Menu:
LB Shell has left the main market (standard) and is due to enter a voluntary liquidation.
LB Shell has left the main market (standard) and is due to enter a voluntary liquidation.
What’s Cooking in the IPO Kitchen?
Main Market (Specialist Funds)
The Global Sustainability Trust -aiming for attractive risk-adjusted returns by investing primarily in private market investments that are expected to have a positive environmental and social impact raising c.£200m. Due 31 Jan 2019.
Circassia Pharma (CIR.L) – specialty pharmaceutical company focused on respiratory disease transferring from the Main Market. No funds being raised. Due 4 Feb.
Greenfields Petroleum (TSX-V:GNF) production focused company with operated assets in Azerbaijan seeking AIM dual listing including $60m private placement. Mkt cap $12.6m CAD. Expected late January 2019.
Itaconix (ITX.L) 6.9p £18.6m
Itaconix has signed an exclusive global supply agreement with Nouryon (formerly AkzoNobel Specialty Chemicals) for Itaconix’s innovative bio-based polymers with chelating properties for the detergents market.
This development follows Itaconix’s announcement in May 2018 that Nouryon notified Itaconix of its desire to enter into a joint marketing effort after completing a successful technical and regulatory evaluation of Itaconix’s polymers.
It is also the first supply agreement resulting from a joint development agreement signed by the companies in 2017 to explore opportunities for polymers made from bio-based itaconic acid using Itaconix’s technology.
Under the terms of the supply agreement, Itaconix will produce and supply certain proprietary polymers with chelating properties that Nouryon will market to its customers in household, institutional, and industrial detergent and cleaner applications.
The Gym Group (GYM.L) 209.5p £289.8m
FYDec18 update from the fast growing, no contract, 24/7, nationwide operator of 159 low cost gyms.
Total year-end membership numbers ahead by 19.3% to 724,000 (Dec 2017: 607,000); Average Members of 693,000 (Dec 2017: 528,000) up 31.2%.
Total revenue growth of 35.6% to £123.9m for the year.
Year-end net debt of £46m (2017: £37.5m) following the easyGym acquisition and investment in 17 new site openings.
“Looking forward we have a good pipeline of new sites and expect to open a further 15-20 gyms in 2019.”
FY Dec 18E £125.2m rev and PBT £15.19m.
FY Dec 19E rev £151.68m and PBT £22.58m.
Forterra (FORT.L) 250p £501m
FYDec18E rev from the UK producer of manufactured masonry products.
“Trading in the final quarter of 2018 was good, underpinned by the sustained strength of the new build residential market. Based on this, full year profit before tax is anticipated to be in line with the Board’s expectations.
Brick volumes for the year were modestly ahead of 2017, and we were able to meet demand through a double digit increase in output reflecting full year production at the Accrington and Claughton facilities, and the investment made in debottlenecking projects. This increase in output meant that brick inventory levels reduced at a lower rate than in 2017, and there was a better balance between sales and production.” Net debt at 31 Dec 2018 was approximately £39m compared with £61m at the start of 2018. FYDec18E rev £360.5m and PBT £63.36m.
Silence Therapeutics (SLN.L) 52.9p £37.6m
The specialist “in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, announces that its lead medicine candidate SLN124 has been granted Orphan Drug Designation by the Committee for Orphan Medicinal Products (COMP), the European Medicines Agency’s (EMA) committee responsible for recommending orphan designations of medicines for rare diseases. This positive COMP decision has been adopted by the European Commission.
Following an application by Silence last year, the COMP concluded that SLN124 will be of significant benefit to those affected by the chronic and potentially life-threatening condition, β-Thalassemia.”
Eden Research (EDEN.L) 11.5p £23.8m
FYDec18 update from company that develops and supplies breakthrough biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries.
The Company has delivered a pleasing year of growth with revenue for the year expected to be in the region of £2.8m, up 48% from £1.9m in 2017, with a loss before tax of approximately £1.0m (2017: loss of £0.8m). Operating profit, excluding share-based payment charges, exceptional royalties refund and amortisation, is expected to be c.£0.02m (2017: loss of £0.6m).
“We are pleased with the overall performance of the business in 2018 and believe that we have established an excellent platform from which we can continue to grow both in 2019 and, importantly, the medium and long term.”
Kape (KAPE.L) 107.3p £152.7m
The consumer security software business, provides an update on trading for the year ended 31 Dec 2018.
The Group performed strongly in the year following initiatives both to grow Kape’s product offering and user base, and to generate higher margin recurring revenues. Adjusted EBITDA for the year is expected to be slightly above market consensus at $10.4m (2017: $8.3m), representing an increase of 25%, with an anticipated increase in underlying Adjusted EBITDA of 70% (2017: $6.1m). This was achieved on revenues for the Group of $56.4m (2017: $66.4m), with the change in revenues anticipated, and as a result of the divestment of the Media business, enabling the Group to fully focus on delivery of cybersecurity solutions. FY Dec 19E rev $56.9m and PBT $9.45m.
Clinigen (CLIN.L) 747.95p £988.73m
FYDec18 update from the he global pharmaceutical and services company.
Revenues increased by around 24% on a reported basis and by around 25% on a constant currency basis compared to last year. Gross profit increased by around 25% on a reported basis and by around 27% on a constant currency basis in line with the Board’s expectations.
The Group completed two corporate acquisitions, CSM and iQone, in October 2018 and two product acquisitions, Proleukin® and Imukin®, in July 2018. Both of the acquired businesses have performed well.
FYJune19E rev £453.25m and PBT £88.1m.
Cloudcall (CALL.L) 95p £22.97m
In line FY Dec 18 update from the cloud-based software business that integrates communications technology into Customer Relationship Management platforms.
Record orders taken in Q4 2018
End-users up 34% year-on-year
Recurring Revenue up 34% year-on-year
Total Revenue up 29% year-on-year
US revenues up 52% year-on-year
End-user growth accelerates through H2 2018, with 724 average monthly net new users added in the half (673 in Q3, 775 in Q4)
FYDec18E rev £9m, PBT loss £3.8m.
TP Group (TPG.L) 6.4p £48.5m
FY Dec 18 update from specialist services and engineering group .
Following a strong performance in the first half of 2018, trading during the remainder of the year remained robust, delivering year-on-year growth in revenue, adjusted operating profit and order book.
The Group is therefore pleased to report that trading for the year ended 31 Dec 2018 has delivered revenue and cash ahead of market expectations, with adjusted operating profit in line with market expectations.
FY Dec18E rev £45.5m and PBT £2.8m.
Tlou Energy (TLOU.L) 11.5p £23.8m
The Company focused on developing gas-to-power projects in southern Africa using coal bed methane natural gas from its gas field in Botswana, announced that the Company’s operational team has recommenced Production Pod drilling at its advanced stage Lesedi CBM project.
Following drilling of the lateral wells, the Lesedi 3 and Lesedi 4 production pods will be completed prior to the installation of surface production facilities. Dewatering and production testing can then begin. Successfully flowing gas at Lesedi 3 & 4 has the potential to upgrade Reserves.
0203 764 2344
*A corporate client of Hybridan LLP
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email email@example.com with “unsubscribe me”.